The trial date for the former University of Kentucky head swim coach accused of sexual abuse has been delayed to January 2027 in U.S. District Court in ...
Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...
A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...
Novo Nordisk shareholders approved the appointment of Lars Rebien Sorensen as new chair as part of a broader move to shake up the company's board of directors at a special meeting on Friday. The ...
Novo Nordisk faces management missteps, pipeline concerns, and aggressive M&A moves, making its stock less attractive compared to peers. LLY is favored for its strong management, robust obesity ...
Novo Nordisk NVO has moved to convene an Extraordinary General Meeting (EGM) after a rare and public disagreement over board composition between its current board of directors and the Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback